PGR and carcinoma: In carcinoma of the LUS, Watanabe et al. found ER- and PR-positive rates of 23.1% (3/13) and 7.7% (1/13), respectively, compared to rates of 54.5% (18/33) for both receptors in non-LUS endometrial cancer, showing a significant reduction of expression in carcinoma of the LUS [6].